Search results

Order by most recent / most popular / relevance

Results: 11-20 of 59

Pfizer v. Pharmascience, merits of NOC proceeding

Gowling Lafleur Henderson LLP
-
Canada
-
January 20 2010

The Court granted prohibition to Pfizer and found that Pharmascience’s allegations of invalidity were not justified

Schering v. Pharmascience, merits of NOC proceeding

Gowling Lafleur Henderson LLP
-
Canada
-
January 20 2010

The application under the NOC Regulations was dismissed

Sanofi v. Hospira, merits of a 55.2 proceeding

Gowling Lafleur Henderson LLP
-
Canada
-
December 3 2009

The Court refused to grant an Order of Prohibition against Hospira regarding its docetaxel product

Pfizer v. ratiopharm, motion to amended a previous judgment on the merits

Gowling Lafleur Henderson LLP
-
Canada
-
December 3 2009

ratiopharm was successful in the proceeding under the NOC Regulations at the trial level, but the decision was overturned on appeal

Bayer Inc. v. Canada (Health), listing decision

Gowling Lafleur Henderson LLP
-
Canada
-
December 3 2009

The Court dismissed a judicial review of the Minister’s decision refusing to list a formulation patent on the Patent Register

Pfizer v. ratiopharm, motion to intervene in appeal of infringement proceedings

Gowling Lafleur Henderson LLP
-
Canada
-
December 3 2009

The Court of Appeal denied BIOTEC Canada’s and Eli Lilly’s leave to intervene in Pfizer’s appeal of the Court’s decision to invalidate a patent for amlodipine

Pfizer v. ratiopharm Inc.; interlocutory motion on appeal of impeachment decision

Gowling Lafleur Henderson LLP
-
Canada
-
December 3 2009

Pfizer filed a motion to amend the contents of its appeal book, its notice of appeal and its memorandum of fact and law on the appeal to deal with the additional grounds

Court injects "duty of candour" requirements for patent agents

Gowling Lafleur Henderson LLP
-
Canada
-
November 24 2009

In a recent decision pursuant to the NOC Regulations, the Federal Court considered s. 73(1) of the Patent Act, and held that there is a duty for patent agents to reply in good faith and make full and frank disclosure to the patent examiner